PE20150287A1 - Composicion farmaceutica que contiene un acido tetrahidrofolico - Google Patents
Composicion farmaceutica que contiene un acido tetrahidrofolicoInfo
- Publication number
- PE20150287A1 PE20150287A1 PE2014002543A PE2014002543A PE20150287A1 PE 20150287 A1 PE20150287 A1 PE 20150287A1 PE 2014002543 A PE2014002543 A PE 2014002543A PE 2014002543 A PE2014002543 A PE 2014002543A PE 20150287 A1 PE20150287 A1 PE 20150287A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical composition
- tetrahydropholic
- composition containing
- progestagen
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN PROGESTAGENO TAL COMO DROSPIRENONA EN UNA CANTIDAD DE 2.5 A 3.5MG; B) UN ESTROGENO TAL COMO ETINILESTRADIOL EN UNA CANTIDAD DE 0.015 A 0.035MG; C) UNA SAL DE CALCIO DEL ACIDO 5-METIL-(6S)-TETRAHIDROFOLICO EN UNA CANTIDAD DE 0.1 A 5MG; D) CELULOSA MICROCRISTALINA EN UNA CANTIDAD DE 10 A 80MG; Y E) LACTOSA MONOHIDRATO EN UNA CANTIDAD DE 10 A 80MG. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION DE LA COMPOSICION. DICHA COMPOSICION ES UTIL COMO ANTICONCEPTIVO ORAL Y PROPORCIONAN BUENA ESTABILIDAD DEL ACIDO TETRAHIDROFOLICO DURANTE EL ALMACENAMIENTO ASEGURANDO NO OBSTANTE UNA LIBERACION RAPIDA Y CONFIABLE DEL ESTROGENO Y DEL PROGESTAGENO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06014002 | 2006-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20150287A1 true PE20150287A1 (es) | 2015-03-15 |
Family
ID=36763829
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000867A PE20080273A1 (es) | 2006-07-06 | 2007-07-05 | Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico |
| PE2011002146A PE20120375A1 (es) | 2006-07-06 | 2007-07-05 | Composicion farmaceutica que contiene un acido tetrahidrofolico |
| PE2014002543A PE20150287A1 (es) | 2006-07-06 | 2007-07-05 | Composicion farmaceutica que contiene un acido tetrahidrofolico |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000867A PE20080273A1 (es) | 2006-07-06 | 2007-07-05 | Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico |
| PE2011002146A PE20120375A1 (es) | 2006-07-06 | 2007-07-05 | Composicion farmaceutica que contiene un acido tetrahidrofolico |
Country Status (31)
| Country | Link |
|---|---|
| EP (2) | EP2422774B1 (es) |
| JP (1) | JP2009542591A (es) |
| KR (2) | KR20090033889A (es) |
| CN (3) | CN101489563A (es) |
| AR (2) | AR061958A1 (es) |
| AU (1) | AU2007271449B2 (es) |
| BR (1) | BRPI0713565B8 (es) |
| CA (2) | CA2656131C (es) |
| CL (1) | CL2007001962A1 (es) |
| CO (1) | CO6150125A2 (es) |
| CR (1) | CR10549A (es) |
| CU (1) | CU20090004A7 (es) |
| EC (1) | ECSP099030A (es) |
| ES (1) | ES2626838T5 (es) |
| GT (1) | GT200900001A (es) |
| IL (3) | IL196027A0 (es) |
| MA (1) | MA30598B1 (es) |
| MX (1) | MX2009000079A (es) |
| MY (1) | MY169516A (es) |
| NO (1) | NO347567B1 (es) |
| NZ (1) | NZ573766A (es) |
| PE (3) | PE20080273A1 (es) |
| PH (1) | PH12012501774B1 (es) |
| RU (2) | RU2479306C2 (es) |
| SG (1) | SG188869A1 (es) |
| TN (1) | TNSN08543A1 (es) |
| TW (2) | TWI508730B (es) |
| UA (2) | UA105078C2 (es) |
| UY (1) | UY30462A1 (es) |
| WO (1) | WO2008003432A1 (es) |
| ZA (4) | ZA200900868B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
| CN101489563A (zh) | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
| US20100317635A1 (en) * | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
| UY32836A (es) * | 2009-08-12 | 2011-03-31 | Bayer Schering Pharma Ag | Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato |
| CN102985070A (zh) * | 2010-04-15 | 2013-03-20 | 拜耳知识产权有限责任公司 | 用于hrt的极低剂量的固体口服剂型 |
| AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
| US11351122B1 (en) | 2010-07-28 | 2022-06-07 | Laboratorios Leon Farma Sa | Synthetic progestogens and pharmaceutical compositions comprising the same |
| US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| CN102516247A (zh) * | 2010-12-15 | 2012-06-27 | 连云港金康医药科技有限公司 | A型l-5-甲基四氢叶酸钙盐多晶型及其制备方法 |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| EP2781214A1 (en) * | 2013-03-22 | 2014-09-24 | Chemo Research, S.L. | Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca) |
| EP2878600B1 (en) | 2013-12-02 | 2018-06-27 | Cerbios-Pharma S.A. | Stable complexes of an alkaline earth metal salt of N5-methyl-tetrahydrofolic acid and a polyol |
| CN107812195B (zh) * | 2014-09-04 | 2021-04-20 | 连云港金康和信药业有限公司 | (6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物 |
| PL3106148T3 (pl) | 2015-06-18 | 2018-08-31 | Mithra Pharmaceuticals S A | Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy |
| CA2988362C (en) | 2015-06-18 | 2022-07-19 | Mithra Pharmaceuticals S.A. | Orodispersible tablet containing estetrol |
| CN107810001A (zh) | 2015-06-18 | 2018-03-16 | 密特拉制药公司 | 含雌四醇的口腔分散片剂 |
| CN107787224A (zh) | 2015-06-18 | 2018-03-09 | 密特拉制药公司 | 含雌四醇组分的口腔分散剂量单位 |
| CN105030779A (zh) * | 2015-07-21 | 2015-11-11 | 福格森（武汉）生物科技股份有限公司 | 一种(6s)-5-甲基四氢叶酸钙口服营养补充剂及其制备方法 |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| CN106336444A (zh) * | 2016-08-23 | 2017-01-18 | 国家卫生计生委科学技术研究所 | 一种新晶型炔雌醇 |
| CN107446458A (zh) * | 2017-08-04 | 2017-12-08 | 合众（佛山）化工有限公司 | 一种高耐水性的丙烯酸改性聚氨酯杂化树脂水性涂料 |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| CN110237046B (zh) * | 2019-03-29 | 2021-07-30 | 福格森（武汉）生物科技股份有限公司 | 一种l-5-甲基四氢叶酸微囊的制备方法 |
| CN110548034A (zh) * | 2019-07-12 | 2019-12-10 | 广州莎蔓生物科技有限公司 | 一种怀孕阻断药物 |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| IT202100008834A1 (it) * | 2021-04-08 | 2022-10-08 | Ind Chimica Srl | Processo per la preparazione di drospirenone come polvere fine tramite duplice cambio di forma cristallina |
| CN114569567B (zh) * | 2021-12-20 | 2023-03-14 | 南通联亚药业股份有限公司 | 一种稳定的双醋炔诺酮炔雌醇复方片及其制备方法 |
| CN115813937B (zh) * | 2022-12-01 | 2025-04-11 | 南通联亚药业股份有限公司 | 一种稳定的包含屈螺酮和雌二醇的药物组合物及其制备方法 |
| TW202535359A (zh) * | 2023-12-20 | 2025-09-16 | 法國商樂斯福公司 | 四氫葉酸鹽固體配方 |
| CN117771389A (zh) * | 2023-12-28 | 2024-03-29 | 浙江圣达生物药业股份有限公司 | L-5-甲基四氢叶酸钙-γ-环糊精包合物及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3347125A1 (de) | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption |
| FR2676927B1 (fr) * | 1991-05-29 | 1995-06-23 | Ibf | Microspheres utilisables pour les occlusions vasculaires therapeutiques et solutions injectables les contenant. |
| TW390813B (en) * | 1994-04-29 | 2000-05-21 | Merck & Co Inc | Wet granulation formulation for bisphosphonic acids |
| DE4426709A1 (de) | 1994-07-20 | 1996-01-25 | Schering Ag | Steroidale Sexualhormone enthaltende feste Arzneiformen |
| KR100384264B1 (ko) | 1994-09-22 | 2003-08-30 | 악조 노벨 엔.브이. | 습식과립화에의한 투여단위의제조방법 |
| RU2073529C1 (ru) * | 1995-05-16 | 1997-02-20 | Центральный научно-исследовательский рентгенорадиологический институт | Композиция для эмболизации кровеносных сосудов |
| CH693255A5 (de) | 1997-06-13 | 2003-05-15 | Eprova Ag | Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels. |
| AU3567699A (en) | 1998-04-17 | 1999-11-08 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| US6214815B1 (en) * | 1998-12-23 | 2001-04-10 | Ortho-Mcneil Pharmaceuticals, Inc. | Triphasic oral contraceptive |
| CH693905A5 (de) * | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
| HRP20020258B1 (hr) * | 1999-08-31 | 2007-05-31 | Schering Aktiengesellschaft | Farmaceutska kombinacija etinilestradiola i drospirenona za upotrebu kao kontracepcijskog sredstva |
| KR101019361B1 (ko) * | 1999-08-31 | 2011-03-07 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 피임약으로서의 사용을 위한 에티닐에스트라디올과드로스피렌온의 약학적 조합 |
| RS52149B (sr) * | 2000-01-18 | 2012-08-31 | Bayer Schering Pharma Aktiengesellschaft | Farmaceutska kombinacija mikronizovanog drospirenona i estrogena za terapiju zamene hormona |
| US6550482B1 (en) * | 2000-04-21 | 2003-04-22 | Vascular Control Systems, Inc. | Methods for non-permanent occlusion of a uterine artery |
| US6864774B2 (en) | 2000-10-19 | 2005-03-08 | Matsushita Electric Industrial Co., Ltd. | Inductance component and method of manufacturing the same |
| EP1216712A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Cyclodextrin-drospirenone inclusion complexes |
| EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
| US6537569B2 (en) * | 2001-02-14 | 2003-03-25 | Microvention, Inc. | Radiation cross-linked hydrogels |
| NZ534806A (en) * | 2002-02-21 | 2006-05-26 | Schering Ag | Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin B12 |
| US20060069168A1 (en) * | 2002-10-29 | 2006-03-30 | Norikazu Tabata | Vascular embolization material |
| UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
| DE112007001600A5 (de) * | 2006-07-06 | 2009-04-30 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen |
| CN101489563A (zh) | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
| RU61120U1 (ru) * | 2006-10-13 | 2007-02-27 | Закрытое акционерное общество "ААА-КОМПАНИ" | Средство для эмболизации сосудов |
| RU62008U1 (ru) * | 2006-10-13 | 2007-03-27 | Закрытое акционерное общество "ААА-КОМПАНИ" | Средство для эмболизации сосудов |
| US8916188B2 (en) * | 2008-04-18 | 2014-12-23 | Abbott Cardiovascular Systems Inc. | Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block |
-
2007
- 2007-05-05 CN CNA2007800254913A patent/CN101489563A/zh active Pending
- 2007-06-21 MY MYPI20070991A patent/MY169516A/en unknown
- 2007-06-25 TW TW096122889A patent/TWI508730B/zh active
- 2007-06-25 TW TW104122823A patent/TW201538161A/zh unknown
- 2007-06-29 UA UAA201207425A patent/UA105078C2/uk unknown
- 2007-06-29 EP EP11190550.1A patent/EP2422774B1/en not_active Revoked
- 2007-06-29 CA CA2656131A patent/CA2656131C/en not_active Expired - Fee Related
- 2007-06-29 EP EP07764936.6A patent/EP2040683B2/en active Active
- 2007-06-29 CA CA2856344A patent/CA2856344C/en not_active Expired - Fee Related
- 2007-06-29 MX MX2009000079A patent/MX2009000079A/es active IP Right Grant
- 2007-06-29 KR KR1020097002386A patent/KR20090033889A/ko not_active Ceased
- 2007-06-29 KR KR1020137006954A patent/KR20130042638A/ko not_active Ceased
- 2007-06-29 CN CN201210143925.2A patent/CN102813663B/zh active Active
- 2007-06-29 AU AU2007271449A patent/AU2007271449B2/en active Active
- 2007-06-29 ES ES07764936T patent/ES2626838T5/es active Active
- 2007-06-29 JP JP2009517003A patent/JP2009542591A/ja active Pending
- 2007-06-29 SG SG2013017165A patent/SG188869A1/en unknown
- 2007-06-29 NZ NZ573766A patent/NZ573766A/en unknown
- 2007-06-29 UA UAA200900637A patent/UA100228C2/uk unknown
- 2007-06-29 CN CN2007800255704A patent/CN101484143B/zh active Active
- 2007-06-29 RU RU2009103649/15A patent/RU2479306C2/ru active
- 2007-06-29 BR BRPI0713565A patent/BRPI0713565B8/pt active IP Right Grant
- 2007-06-29 NO NO20090578A patent/NO347567B1/no unknown
- 2007-06-29 WO PCT/EP2007/005764 patent/WO2008003432A1/en not_active Ceased
- 2007-07-04 UY UY30462A patent/UY30462A1/es not_active Application Discontinuation
- 2007-07-05 PE PE2007000867A patent/PE20080273A1/es not_active Application Discontinuation
- 2007-07-05 PE PE2011002146A patent/PE20120375A1/es active IP Right Grant
- 2007-07-05 PE PE2014002543A patent/PE20150287A1/es active IP Right Grant
- 2007-07-05 CL CL2007001962A patent/CL2007001962A1/es unknown
- 2007-07-06 AR ARP070103016A patent/AR061958A1/es not_active Application Discontinuation
-
2008
- 2008-12-18 IL IL196027A patent/IL196027A0/en active IP Right Grant
- 2008-12-31 TN TNP2008000543A patent/TNSN08543A1/en unknown
-
2009
- 2009-01-05 EC EC2009009030A patent/ECSP099030A/es unknown
- 2009-01-06 CR CR10549A patent/CR10549A/es not_active Application Discontinuation
- 2009-01-06 CO CO09000752A patent/CO6150125A2/es unknown
- 2009-01-06 CU CU2009000004A patent/CU20090004A7/es active IP Right Grant
- 2009-01-06 GT GT200900001A patent/GT200900001A/es unknown
- 2009-01-23 MA MA31584A patent/MA30598B1/fr unknown
- 2009-02-05 ZA ZA2009/00868A patent/ZA200900868B/en unknown
-
2012
- 2012-08-02 RU RU2012133154A patent/RU2624236C2/ru active
- 2012-09-06 PH PH12012501774A patent/PH12012501774B1/en unknown
-
2013
- 2013-01-30 IL IL224484A patent/IL224484A/en active IP Right Grant
-
2015
- 2015-03-11 ZA ZA2015/01673A patent/ZA201501673B/en unknown
-
2016
- 2016-04-21 IL IL245355A patent/IL245355B/en active IP Right Grant
- 2016-11-03 AR ARP160103347A patent/AR106561A2/es not_active Application Discontinuation
-
2018
- 2018-11-29 ZA ZA2018/08084A patent/ZA201808084B/en unknown
- 2018-11-29 ZA ZA2018/08083A patent/ZA201808083B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20150287A1 (es) | Composicion farmaceutica que contiene un acido tetrahidrofolico | |
| MX385798B (es) | Composiciones orales que contienen un ester de 17-hidroxiprogesterona y metodos relacionados. | |
| UY30461A1 (es) | Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas. | |
| WO2013022783A3 (en) | Progesterone containing oral dosage forms and related methods | |
| PE20070208A1 (es) | Anticoncepcion oral con trimegestona | |
| BR0317275A (pt) | Liberação controlada de uma substância ativa em um ambiente de gordura alta | |
| BR112012007412A2 (pt) | tabletes transformáveis de forma oral. | |
| CY1109910T1 (el) | Χρηση μιας υδροφιλης μητρας η οποια περιεχει ενα παραγωγο πολυακρυλικου οξεος, εναν αιθερα κυτταρινης και εναν παραγοντα αποσαθρωσης για την παραγωγη ενος φαρμακου για την αγωγη ασθενειων των γυναικειων γεννητικων οργανων | |
| JP2009528372A5 (es) | ||
| PE20120860A1 (es) | Combinacion farmaceutica que comprende levonorgestrel en combinacion con piroxicam, indometacina o diclofenaco | |
| NZ590291A (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| BR112013006597A2 (pt) | tablete para desintegração oral em múltiplas camadas, e a fabricação do mesmo | |
| EA201201403A1 (ru) | Очень низкодозированные твердые пероральные лекарственные формы для гзт | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| PE20070327A1 (es) | Composicion que comprende una progestina y un estrogeno | |
| NZ605176A (en) | Pharmaceutical composition comprising drospirenone and contraceptive kit | |
| MX2009003030A (es) | Forma galenita para la administracion por via transmucosa de principios activos. | |
| PE20130210A1 (es) | Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph | |
| CL2011001178A1 (es) | Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia. | |
| PE20070192A1 (es) | Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina | |
| AR111649A1 (es) | Anillo vaginal para la liberación simultánea de dos ingredientes activos | |
| BR0008057A (pt) | Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada | |
| PE20060318A1 (es) | Forma de administracion para la contracepcion hormonal | |
| HRP20230762T1 (hr) | Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama | |
| WO2010089259A3 (en) | Sustained release composition containing quetiapine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |